Skip to Main Content

Paper Details

Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in <i>TP53</i> wild-type Ewing sarcoma.
J Exp Med
50
2018
ATSP-7041, Cas9, ETS, EWS, Ewing sarcoma, Ewing sarcoma cells, GSK2830371, MDM2, MDM4, P5091, PPM1D, TP53, TP53 wild, TP53 wild-type Ewing sarcoma, USP7, Wip1, XL-188, mouse, p53, patients, pediatric cancer, tumor, tumors, wild-type TP53
Author NameAffiliation
Gabriela AlexeDana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School
Gabriela AlexeBoston University
Gabriela AlexeThe Broad Institute of MIT and Harvard
Gabriela AlexeDana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School
Gabriela AlexeThe Broad Institute of MIT and Harvard
Gabriela AlexeBoston University
Aviad TsherniakThe Broad Institute of MIT and Harvard
Aviad TsherniakThe Broad Institute of MIT and Harvard
Francisca VazquezThe Broad Institute of MIT and Harvard
Kimberly StegmaierDana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School
Kimberly StegmaierThe Broad Institute of MIT and Harvard
Kimberly StegmaierDana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School
Kimberly StegmaierThe Broad Institute of MIT and Harvard
  • 1 - 13

Datasets

Release 1.2